COMMUNIQUÉS West-GlobeNewswire

On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants Completed in 48 Hours
13/08/2025
RIYADH, Saudi Arabia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) successfully performed 10 kidney exchange transplants over two consecutive days, setting a global [...]
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
13/08/2025
PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of [...]
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
13/08/2025
Business development : Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently [...]
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
13/08/2025
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor [...]
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
13/08/2025
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
13/08/2025
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and [...]
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
13/08/2025
Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveil ed a Long-Acting GLP-1 Receptor [...]
ElevateBio BaseCamp Achieves ICMC™ Certification for Commercial Cell and Gene Therapy Manufacturing Capabilities
13/08/2025
ICMC certification delivered by Dark Horse Consulting certifies ElevateBio’s compliant and scalable manufacturing capabilities for advanced therapies using U.S. and E.U. commercial-level evaluation standards BaseCamp is [...]
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
13/08/2025
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology [...]
FOXO TECHNOLOGIES INC. ANNOUNCES THAT ITS COMMON STOCK CAN BE QUOTED AND TRADED ON THE OVER THE COUNTER MARKET FROM AUGUST 13, 2025.
13/08/2025
WEST PALM BEACH, FLORIDA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (“ FOXO ” or the “ Company ”) announces that it has received a letter from NYSE on August 12, 2025 confirming that NYSE Regulation has [...]
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
13/08/2025
ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’ [...]
ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025
13/08/2025
ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart ™ [...]
BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology
13/08/2025
SUNNYVALE, Calif. and UTRECHT, Netherlands, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and [...]
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
13/08/2025
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients [...]
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
13/08/2025
Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone [...]
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
13/08/2025
Multiple Announcements of Clinical Data Results Anticipated in Q3 2025 SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on [...]
First LockeT Cases Completed in Germany
13/08/2025
FORT MILL, S.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Clene to Present at the Emerging Growth Conference
13/08/2025
SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
13/08/2025
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage [...]

Pages